Awaiting development: Guidance and quality standards

Showing 21 to 30 of 344

Guidance and quality standards awaiting development
Title	Type
Aquablation robotic therapy for lower urinary tract symptoms caused by benign prostatic hyperplasia	Medical technologies guidance
Artificial Intelligence assisted Echocardiography to support diagnosis of heart failure: Early Value Assessment	Health technology evaluation
Artificial intelligence technologies for mammography: early value assessment	Health technology evaluation
Astegolimab as add-on maintenance treatment for moderate to severe chronic obstructive pulmonary disease [ID6524]	Technology appraisal guidance
Atezolizumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID3894]	Technology appraisal guidance
Atezolizumab for adjuvant treatment of circulating tumour DNA-positive high-risk muscle-invasive bladder cancer after cystectomy [ID6515]	Technology appraisal guidance
Atrasentan for treating primary IgA nephropathy [ID6588]	Technology appraisal guidance
Avacincaptad pegol for treating geographic atrophy caused by age-related macular degeneration [ID6401]	Technology appraisal guidance
Axatilimab for treating active chronic graft-versus-host disease after 2 or more systemic treatments in people 2 years and over [ID6570]	Technology appraisal guidance
Balloon cryoablation for Barrett's oesophagus	Interventional procedures guidance